Skip to content

Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy

A Artificial Intelligence Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06285058
Enrollment
1000
Registered
2024-02-29
Start date
2024-03-31
Completion date
2026-03-31
Last updated
2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Learning Model, Neoadjuvant Chemoimmunotherapy, Non-small Cell Lung Cancer, Pathological Complete Response

Brief summary

This study presents the development and validation of an artificial intelligence (AI) prediction system that utilizes pre-neoadjuvant immunotherapy plain scans and enhanced multimodal CT scans to extract deep learning features. The aim is to predict the occurrence of pathological complete response in non-small cell lung cancer patients undergoing neoadjuvant immunochemotherapyy.

Detailed description

This study retrospectively obtained non-contrast enhanced and contrast enhanced CT scans of patients with NSCLC who underwent surgery after receiving neoadjuvant immunochemotherapy. at multiple centers between August 2019 and February 2023. Deep learning features were extracted from both non-contract enhanced and contract enhanced CT scans to construct the predictive models (LUNAI-nCT model and LUNAI-eCT model), respectively. After feature fusion of these two types of features, a fused model (LUNAI-fCT model) was constructed. The performance of the model was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). SHapley Additive exPlanations (SHAP) analysis was used to quantify the impact of CT imaging features on model prediction. To gain insights into how our model makes predictions, we employed Gradient-weighted Class Activation Mapping (Grad-CAM) to generate saliency heatmaps.

Interventions

DIAGNOSTIC_TESTNo interventions

The high-throughput extraction of large amounts of quantitative image features from medical images

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients' with non-small cell lung cancer, diagnosed through biopsy pathology and clinically classified as stage IB to III; 2. Patients who receive at least two cycles of neoadjuvant immunotherapy combined with chemotherapy induction therapy; 3. According to the IASLC guidelines, postoperative pathological evaluation was performed on the treatment response of the tumor primary lesion and lymph nodes.

Exclusion criteria

1. Missing or inadequate quality of CT; 2. Time interval between CT and start of treatment is greater than 1 month; 3. Incomplete clinicopathologic data.

Design outcomes

Primary

MeasureTime frameDescription
the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of predicting modelBaseline treatmentseveral metrics were calculated, including accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026